Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueReturn on AssetsReturn on Sales

Mainz Biomed (MYNZ) EBITDA Margin (2022 - 2023)

Historic EBITDA Margin for Mainz Biomed (MYNZ) over the last 2 years, with Q4 2023 value amounting to 22155.68%.

  • Mainz Biomed's EBITDA Margin fell 178153700.0% to 22155.68% in Q4 2023 from the same period last year, while for Dec 2023 it was 2992.84%, marking a year-over-year decrease of 48164600.0%. This contributed to the annual value of 2433.49% for FY2024, which is 54263300.0% up from last year.
  • Per Mainz Biomed's latest filing, its EBITDA Margin stood at 22155.68% for Q4 2023, which was down 178153700.0% from 3202.69% recorded in Q3 2023.
  • Mainz Biomed's EBITDA Margin's 5-year high stood at 5715.54% during Q3 2022, with a 5-year trough of 22155.68% in Q4 2023.